Fidelity SPDR Advertisement
Home > Boards > US OTC > Medical - Drugs >

Ocata Therapeutics Inc. (OCAT)

Add OCAT Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator sports guy, Auger08, Kapla, LODE MAKING ME RICH, homeslice10, lasers
Search This Board:
Last Post: 11/28/2014 5:11:15 PM - Followers: 638 - Board type: Free - Posts Today: 0

 Ocata Therapeutics (OCAT)

formerly Advanced Cell Technology (ACTC):
Advanced Cell Technology Changes Name to Ocata Therapeutics

Ocata Therapeutics Headquarters
33 Locke Drive
Marlborough, MA 01752
Tel: (508) 756-1212
Fax: (508) 229-2333 

Company Overview

Ocata Therapeutics, Inc. (“Ocata”; OTCBB: OCAT), formerly named Advanced Cell Technology, is a clinical stage biotechnology company focused on the development and commercialization of new therapies in the field of regenerative medicine. Regenerative medicine is defined as the process of replacing or regenerating human cells, tissues or organs to restore or establish normal function and has been called the “next evolution of medical treatments” and “the vanguard of 21st century healthcare” by the U.S. Department of Health and Human Services.

The company’s principal R&D and commercial efforts relate to its Regenerative Ophthalmology™ programs and involve development of therapies for the treatment of eye diseases and disorders. Beyond the eye, our other research areas include projects focusing on developing many different cell therapies that may be used to treat a range of diseases across several therapeutic categories. Ocata’s principal laboratory, GMP facility and corporate offices are in Marlborough, Massachusetts. 

Regenerative Ophthalmology Platform

The mission behind our Regenerative Ophthalmology efforts is clear. It is our goal to bring innovative new therapies to the market to treat diseases of the eye that otherwise may cause significant loss of vision in patients. Our emerging cell therapies focus on structural repair and functional restoration and have the potential to make a significant difference in the lives of people with ocular disorders.

We are at the forefront of developing new therapies to address some of the most significant unmet medical needs in eye diseases. These include potential treatments for diseases affecting the retina, such as age-related macular degeneration – as well as other forms of macular degeneration, diabetic retinopathy and retinitis pigmentosa, as well as inflammatory diseases such as uveitis, and vision loss from photoreceptor and other neurosensory retinal damage due to glaucoma.

  • Our lead clinical program involves RPE Cell Therapy for treating macular degeneration. Critical to the development and the rate of progression of macular degeneration is the health status of the retinal pigment epithelium, or RPE, a single layer of cells whose presence and integrity in the retina are required for normal vision. The company is currently conducting clinical trials in the U.S. andU.K. for treating Stargardt’s macular degeneration with the RPE Cell Therapy, and in the U.S. for treating patients with dry age-related macular degeneration.
    We are developing a Photoreceptor Progenitor Cell Therapy which we intend to be used for treating a wide variety of retinal degenerations in diseases where photoreceptors malfunction and/or die.
    Our Ganglion Progenitor Cell Therapy is a preclinical candidate program. In animal models of glaucoma, the injection of these cells protects against damage of existing nerve cells as well as forms new ganglion nerve cells.
    The company is also developing therapeutic platforms using Corneal Endothelial Cells for use in treating corneal blindness.

See our Pipeline of Ophthalmology Therapies »

Other Regenerative Medicine Programs

In addition to our regenerative ophthalmology programs we have invested in other programs where we feel that we can leverage our expertise in cellular and developmental biology to generate allogeneic therapies that have the potential to improve health care in other prevalent degenerative diseases and diseases of aging. At the core of our pipeline planning are approaches intended to address large unmet medical needs with allogeneic stem cell-derived therapeutics.

Our Mesenchymal Stem Cells

Our Mesenchymal Stem Cells (MSCs) represent an “off-the-shelf” cellular therapy ready for treatment of autoimmune and inflammatory diseases in both acute and chronic settings. MSCs regulate immune and inflammatory responses, providing therapeutic potential for treating diseases characterized by the presence of an inflammatory component, which makes them an attractive tool for the cellular treatment of autoimmunity and inflammation. We believe we have succeeded at creating a differentiated MSC product by producing the cells in culture from a pluripotent stem cell source.

Neuroprotective Biologics

We have discovered Neuroprotective Biologics that are secreted by certain of our neurosensory retina progenitor cell populations. We anticipate that the neuroprotective agent(s) that we may ultimately develop as drug candidates may be useful not only in retinal diseases and dystrophies, but may have broader applications in central nervous system and peripheral nervous system diseases and disorders, including diseases causing cognitive function impairment, movement disorders such as Parkinson’s Disease, and ischemic events such as caused by stroke.

Blood Components Programs

Through our Blood Components Programs, we have been able to generate Red Blood Cells, Platelets, Dendritic cells and other cells relevant immune response or hemostasis.


Pipeline of Therapeutic Programs

Ocata’s world-class research and development programs embody our efforts to bring transformative new therapies to market for patients facing some of hardest-to-treat eye diseases and disorders.




Press Releases

November 25, 2014

Ocata Therapeutics to Present at 26th Annual Piper Jaffray Health Care Conference

November 24, 2014

Ocata Therapeutics Receives Advanced Therapy Medicinal Product Designation from the European Medicines Agency

November 14, 2014

Advanced Cell Technology Changes Name to Ocata Therapeutics

November 7, 2014

Advanced Cell Technology to Host Conference Call and Webcast to Provide a Corporate Update for the Third Quarter of 2014

October 20, 2014

Advanced Cell Technology Appoints LeRoux Jooste as SVP of Business Development & Chief Commercial Officer

October 17, 2014

ACT Reports the Publication of Research on the Scalable Generation of Universal Platelets from Human Induced Pluripotent Stem Cells (iPSC)

October 14, 2014

ACT Announces Positive Results from Two Clinical Trials Published in The Lancet Using Differentiated Stem Cell-Derived Retinal Pigment Epithelium (RPE) Cells for the Treatment of Macular Degeneration

September 25, 2014

Advanced Cell Technology Announces Final Patient Treated in Stargardt’s Macular Degeneration Phase 1 Trial in the United Kingdom

September 5, 2014

Advanced Cell Technology Announces Issuance of Patent Covering Dendritic Cells Manufacturing from Renewable Stem Cell Sources

September 2, 2014

Distinguished Scientists Join Advanced Cell Technology’s New Scientific Advisory Board


All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.




Rules of the board according to IHUB:


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
ACTC News: OTC Stocks Daily Trading Focus: Windstream Technologies, Inc. Blue Earth, Inc. Creative Edge Nutrition, Inc. Brainstorm Cell ... 07/01/2014 08:00:00 AM
ACTC News: OTC Stocks Daily Trading Focus: Windstream Technologies, Inc. Blue Earth, Inc. Creative Edge Nutrition, Inc. Brainstorm Cell ... 07/01/2014 08:00:00 AM
#76767  Sticky Note Ocata Therapeutics Receives Advanced Therapy Medicinal Product Designation lasers 11/24/14 12:12:44 PM
#74805  Sticky Note ACT Announces Positive Results from Two Clinical Trials LittleDutchDenny 10/14/14 09:50:43 PM
#76859   I'M SUPRISED THIS FLUFF STAYED UP FOR THIS LONG! locksflooring 11/28/14 05:11:15 PM
#76858 andyshow 11/27/14 04:11:58 PM
#76857   You won't qualify for disability for long homeslice10 11/27/14 03:54:51 PM
#76856   Happy Thanksgiving all Ocata investors! Auger08 11/27/14 03:46:17 PM
#76855 chuckanutman 11/27/14 11:47:07 AM
#76854   Thankfull Thoughts chuckanutman 11/27/14 11:43:28 AM
#76853   As I said before, I am adding LODE MAKING ME RICH 11/27/14 11:32:01 AM
#76852   And you Sportsguy. Thankyou. Gastrodamas 11/27/14 11:30:52 AM
#76851   HOPE U ALL ENJOY YOR FAMILIES HAPPY THANKSGIVING TO sports guy 11/27/14 11:19:14 AM
#76850   No better time to do it homeslice10 11/26/14 08:55:13 PM
#76849   As a general rule I agree, but with elysse1kittycat 11/26/14 08:37:57 PM
#76848   That's surely my observation as well. farviewhill 11/26/14 08:36:55 PM
#76847   Being treated the same as the 3rd Quarter AyeEye 11/26/14 08:24:39 PM
#76846   Correction, 90 days. Auger08 11/26/14 07:44:00 PM
#76845   They seem to be pretty proud of what Auger08 11/26/14 07:42:33 PM
#76844   In my experience when the CEO makes a smokey 11/26/14 06:35:37 PM
#76843   December 2nd. Auger08 11/26/14 04:11:55 PM
#76842   When exactly is this confers car? I know BRZlimited92 11/26/14 03:32:42 PM
#76841   Just pondering if OCAT should consider a delayed AyeEye 11/26/14 12:52:41 PM
#76840   PW has a "prime time speaking spot, at chuckanutman 11/26/14 09:32:33 AM
#76839   It's pretty safe to say, you're only as farviewhill 11/26/14 12:43:27 AM
#76838   At first I thought this vp was too homeslice10 11/25/14 11:22:31 PM
#76837   Interesting OCATA post from Icell: chuckanutman 11/25/14 11:01:39 PM
#76836   Exactly. As overly prematurely generous as this seems, the farviewhill 11/25/14 10:31:43 PM
#76835   Payment in shares is taxed at the value homeslice10 11/25/14 09:59:46 PM
#76834   Jooste shares: No pun intended, but quite a Reetala 11/25/14 08:28:22 PM
#76833   Waiting for uplist as was stated by management. Gastrodamas 11/25/14 07:43:10 PM
#76832   Jootse and what has he done lately to Gastrodamas 11/25/14 07:38:11 PM
#76831   Still like to read your posts. Gastrodamas 11/25/14 07:31:21 PM
#76830   10-4 goodbuddy. Gastrodamas 11/25/14 07:20:29 PM
#76829   25,000 shares @ 158k bonus right off the fulleroots 11/25/14 06:25:57 PM
#76828   Form 4 for Jooste Reetala 11/25/14 05:33:42 PM
#76827   As it stands now, all we see each elysse1kittycat 11/25/14 04:26:40 PM
#76826   Advanced Cell Technology: All Systems Go Goodbuddy4863 11/25/14 03:54:06 PM
#76825   Your persistence and determination is self evident, i'm chuckanutman 11/25/14 03:52:31 PM
#76824   How many of those patient 45000 investors have elysse1kittycat 11/25/14 03:44:49 PM
#76823   Excellent post and for all those reasons you Scrooge McWeb 11/25/14 03:43:33 PM
#76822   Farviewhill, your best post ever. chuckanutman 11/25/14 03:40:05 PM
#76821   As frustrated as most all of us are farviewhill 11/25/14 03:15:57 PM
#76820   What else can we do, everyone please excuse fulleroots 11/25/14 02:25:10 PM
#76819   Thanks for the giggles Fuller! Gotta laugh at anselab 11/25/14 02:06:12 PM
#76818   The "select few" (45,000) could be very patient. chuckanutman 11/25/14 01:00:38 PM
#76817   Patience? lol he just don't know does he. fulleroots 11/25/14 12:53:06 PM
#76816   For me the stock Market overall is a elysse1kittycat 11/25/14 12:46:39 PM
#76815   Sorry Chuck-I might have been a little paranoid elysse1kittycat 11/25/14 12:44:03 PM
#76814   The Stock Market is a device for transferring chuckanutman 11/25/14 12:42:45 PM
#76813   Are you? we are lower than Gary's fulleroots 11/25/14 12:38:30 PM
#76812   Are you keeping track of OCAT progress? I chuckanutman 11/25/14 12:34:08 PM
#76811   I don't quite understand what you mean here. elysse1kittycat 11/25/14 12:26:49 PM
#76809   And at least for now the stock is elysse1kittycat 11/25/14 11:59:47 AM